Amiral Gestion Has $21.99 Million Position in Edwards Lifesciences Corporation $EW

Amiral Gestion raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 156.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 282,795 shares of the medical research company’s stock after purchasing an additional 172,481 shares during the quarter. Edwards Lifesciences accounts for about 8.0% of Amiral Gestion’s investment portfolio, making the stock its 4th biggest position. Amiral Gestion’s holdings in Edwards Lifesciences were worth $21,993,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock valued at $5,474,515,000 after purchasing an additional 798,801 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after buying an additional 45,555 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after buying an additional 1,584,958 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after acquiring an additional 4,805,819 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $580,640,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus set a $100.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, December 5th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $90.00 to $100.00 in a research report on Thursday. Truist Financial set a $92.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, December 5th. Barclays reaffirmed an “overweight” rating and issued a $103.00 price objective (up from $99.00) on shares of Edwards Lifesciences in a research report on Monday, December 8th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $93.95.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at $3,264,127.20. The trade was a 22.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $84.03, for a total transaction of $85,626.57. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,848,828.06. This represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,465 shares of company stock valued at $3,804,610 in the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $84.73 on Friday. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a market cap of $49.17 billion, a PE ratio of 36.52, a price-to-earnings-growth ratio of 3.81 and a beta of 0.97. The business’s 50 day moving average price is $82.30 and its two-hundred day moving average price is $79.22. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.